Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1231
Healthy volunteers: no

Brief summary:
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2 diabetes.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: semaglutide intervention 2: sitagliptin intervention 3: placebo intervention 4: placebo
Intervention descriptions: intervention 1: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication. intervention 2: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication. intervention 3: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication. intervention 4: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.

Protocol document: